Cleared Traditional

K800238 - MOIRE FRINGE VISOMETER AFTER LOTMAR

K800238 is the FDA 510(k) clearance for MOIRE FRINGE VISOMETER AFTER LOTMAR by Hagg-Streit Service, Inc.. It is a Class 2 Ophthalmic device (product code HKL) cleared through the Traditional 510(k) pathway after a 34-day FDA review.

K800238 · Hagg-Streit Service, Inc. · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 1980
Decision
34d
Days
Class 2
Risk

K800238 is an FDA 510(k) clearance for the MOIRE FRINGE VISOMETER AFTER LOTMAR. Classified as Retinoscope, Ac-powered (product code HKL), Class II - Special Controls.

Submitted by Hagg-Streit Service, Inc. (Mchenry, US). The FDA issued a Cleared decision on March 10, 1980 after a review of 34 days - a notably fast clearance cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.1780 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Hagg-Streit Service, Inc. devices

Submission Details

510(k) Number K800238 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 05, 1980
Decision Date March 10, 1980
Days to Decision 34 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
76d faster than avg
Panel avg: 110d · This submission: 34d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code HKL Retinoscope, Ac-powered
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 886.1780
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Ophthalmic devices follow this clearance model.